[Treatment of irritable bowel syndrome with Escherichia coli strain Nissle 1917 (EcN): a retrospective survey] - PubMed (original) (raw)
. 2007 Nov 15;102(11):888-92.
doi: 10.1007/s00063-007-1116-2.
[Article in German]
Affiliations
- PMID: 17992479
- DOI: 10.1007/s00063-007-1116-2
[Treatment of irritable bowel syndrome with Escherichia coli strain Nissle 1917 (EcN): a retrospective survey]
[Article in German]
Dominik Plassmann et al. Med Klin (Munich). 2007.
Abstract
Background and purpose: In many patients with irritable bowel syndrome (IBS), one symptom is predominant (e.g., diarrhea, constipation, meteorism, or alternating stool consistency). For IBS therapy, probiotic drugs such as Mutaflor (active ingredient: Escherichia coli strain Nissle 1917 [EcN]) are also being used. A systematic survey on the efficacy and safety of EcN in different IBS subgroups is still missing.
Patients and methods: In a gastroenterologic outpatient practice, results of 150 IBS patients treated with EcN were evaluated retrospectively. Most IBS patients enrolled belonged to the subgroups "diarrhea", "meteorism", and "alternating stool consistency".
Results: Regarding the diarrhea subgroup, not only a statistically significant improvement in stool frequency was observed, but also a marked improvement in concomitant symptoms such as abnormal urge, flatulence, and abdominal fullness. These complaints improved under EcN therapy in the other IBS subgroups as well, so that efficacy was assessed as "good to very good" in 73.4% of all cases. Tolerance to treatment was "good to very good" in 97.9% of the cases.
Conclusion: The results point to the possibility of EcN being a therapeutic option for patients of various IBS subgroups which is almost free of side effects.
Similar articles
- [Probiotic drug therapy with E. coli strain Nissle 1917 (EcN): results of a prospective study of the records of 3,807 patients].
Krammer HJ, Kämper H, von Bünau R, Zieseniss E, Stange C, Schlieger F, Clever I, Schulze J. Krammer HJ, et al. Z Gastroenterol. 2006 Aug;44(8):651-6. doi: 10.1055/s-2006-926909. Z Gastroenterol. 2006. PMID: 16902895 Clinical Trial. German. - A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.
Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P. Drouault-Holowacz S, et al. Gastroenterol Clin Biol. 2008 Feb;32(2):147-52. doi: 10.1016/j.gcb.2007.06.001. Epub 2008 Mar 4. Gastroenterol Clin Biol. 2008. PMID: 18387426 Clinical Trial. - Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo.
Enck P, Zimmermann K, Menke G, Klosterhalfen S. Enck P, et al. Z Gastroenterol. 2009 Feb;47(2):209-14. doi: 10.1055/s-2008-1027702. Epub 2009 Feb 5. Z Gastroenterol. 2009. PMID: 19197823 Clinical Trial. - [Probiotic therapy of the irritable bowel syndrome].
Enck P, Klosterhalfen S, Martens U. Enck P, et al. Dtsch Med Wochenschr. 2011 Feb;136(8):371-5. doi: 10.1055/s-0031-1272538. Epub 2011 Feb 17. Dtsch Med Wochenschr. 2011. PMID: 21332036 Review. German. - Effectiveness of probiotics in the treatment of irritable bowel syndrome.
Wilhelm SM, Brubaker CM, Varcak EA, Kale-Pradhan PB. Wilhelm SM, et al. Pharmacotherapy. 2008 Apr;28(4):496-505. doi: 10.1592/phco.28.4.496. Pharmacotherapy. 2008. PMID: 18363533 Review.
Cited by
- Probiotic Escherichia coli Ameliorates Antibiotic-Associated Anxiety Responses in Mice.
Park K, Park S, Nagappan A, Ray N, Kim J, Yoon S, Moon Y. Park K, et al. Nutrients. 2021 Mar 1;13(3):811. doi: 10.3390/nu13030811. Nutrients. 2021. PMID: 33804493 Free PMC article. - Worm-Based Alternate Assessment of Probiotic Intervention against Gut Barrier Infection.
Kim J, Moon Y. Kim J, et al. Nutrients. 2019 Sep 8;11(9):2146. doi: 10.3390/nu11092146. Nutrients. 2019. PMID: 31500368 Free PMC article. - Nononcogenic restoration of the intestinal barrier by E. coli-delivered human EGF.
Yu M, Kim J, Ahn JH, Moon Y. Yu M, et al. JCI Insight. 2019 Aug 22;4(16):e125166. doi: 10.1172/jci.insight.125166. JCI Insight. 2019. PMID: 31434808 Free PMC article. - Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update.
Scaldaferri F, Gerardi V, Mangiola F, Lopetuso LR, Pizzoferrato M, Petito V, Papa A, Stojanovic J, Poscia A, Cammarota G, Gasbarrini A. Scaldaferri F, et al. World J Gastroenterol. 2016 Jun 28;22(24):5505-11. doi: 10.3748/wjg.v22.i24.5505. World J Gastroenterol. 2016. PMID: 27350728 Free PMC article. Review. - The role of probiotics and prebiotics in inducing gut immunity.
Vieira AT, Teixeira MM, Martins FS. Vieira AT, et al. Front Immunol. 2013 Dec 12;4:445. doi: 10.3389/fimmu.2013.00445. Front Immunol. 2013. PMID: 24376446 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources